Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2018-12-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
2018年度非公开发行A股股票预案
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票预案" which translates to "Non-public Offering of Shares Proposal". It details the plan for a non-public issuance of A shares by 嘉事堂药业股份有限公司 (Cachet Pharmaceutical Co., Ltd.) in 2018. The content includes the background, purpose, issuance scheme, pricing, issuance quantity, use of proceeds, related party transactions, and approval procedures. It is a comprehensive plan document related to capital raising through a non-public share issuance. There is no indication that this is an announcement of a report publication or a brief summary. The document is lengthy (15,000 characters) and contains detailed financial and strategic information about the capital raising. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Therefore, the document should be classified as CAP with high confidence.
2018-12-14 Chinese
关于非公开发行股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Analysis Report on the Use of Funds Raised from Non-public Issuance of Shares" by 嘉事堂药业股份有限公司. It discusses the plan for using the raised funds, necessity and feasibility of supplementing working capital, financial impact analysis, and projections related to the company's capital structure and financial health. The content is focused on capital raising and the use of proceeds from a non-public stock issuance, including detailed financial and operational analysis related to this financing activity. There is no indication that this is an annual report, audit report, earnings release, or other types of reports. Instead, it is a detailed capital/financing update related to a specific fundraising event. Therefore, the document fits best under the category "Capital/Financing Update (CAP)".
2018-12-14 Chinese
关于公司本次非公开发行股票涉及关联交易事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-public issuance of shares by 嘉事堂药业股份有限公司 (Jia Shi Tang Pharmaceutical Co., Ltd.) involving a related party transaction with China Everbright Group. It details the transaction terms, pricing policy, approval procedures, and independent directors' opinions. The document is a formal announcement of a capital raising event through a private placement of shares, including information about the related party nature of the transaction and regulatory approvals required. It does not contain financial statements or comprehensive financial data but focuses on the capital issuance and related transaction details. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (5266 characters) and content confirm it is the announcement itself, not a report publication or regulatory filing. Hence, the classification is CAP with high confidence.
2018-12-14 Chinese
第五届监事会第二十二次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a supervisory board meeting regarding a non-public stock issuance plan. It includes voting results, references to compliance with Chinese securities laws, and mentions that the proposals require shareholder approval. The content focuses on the approval of a capital raising plan through non-public issuance of shares, including details on pricing, lock-up periods, and use of proceeds. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing, but a formal announcement of financing decisions by the board.
2018-12-14 Chinese
未来三年（2018-2020年）股东回报规划
Governance Information Classification · 95% confidence The document is a detailed statement of the company's shareholder return plan for the years 2018-2020, outlining principles, decision-making procedures, and policies related to profit distribution and dividends. It is not a financial report, earnings release, or regulatory filing but a formal policy document issued by the board. It does not contain financial statements or results but focuses on governance and shareholder return strategy. This fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices including dividend and shareholder return policies.
2018-12-14 Chinese
前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by 嘉事堂药业股份有限公司, including amounts raised, allocation, investment projects, and compliance with regulatory requirements. It references regulatory approvals from the China Securities Regulatory Commission and includes financial figures and project progress up to September 30, 2018. The content focuses on the use of capital raised through a non-public stock issuance, detailing the management and investment of those funds, which aligns with a capital/financing update rather than a full annual or interim financial report. The document is substantive and exceeds 5,000 characters, so it is not merely an announcement. It is not an audit report, earnings release, or management report. Therefore, the best fitting category is Capital/Financing Update (CAP).
2018-12-14 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.